Pharmacogenomics to predict drug response

Pharmacogenomics

Volumn 1, Issue 1, 2000, Pages 5-14

  Adam, Gail I R ^a   Reneland, Richard ^a   Andersson, Maria ^a   Risinger, Carl ^a   Nilsson, Mats ^a   Lewander, Tommy ^a  

^a Gemini Holdings plc Group   (Sweden)

Author keywords

CYP (cytochrome P450); DNA; Drug efficacy; Genetic tests; Genomic; Human; Pharmaceutical; Polymorphism; Single nucleotide polymorphism (SNP); Treatment response; Variation

Indexed keywords

DRUG THERAPY; HUMAN; METHODOLOGY; PHARMACOGENETICS; PHARMACOLOGY; REVIEW;

DRUG THERAPY; HUMANS; PHARMACOGENETICS; PHARMACOLOGY; RESEARCH DESIGN;

EID: 0034139470     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.1.1.5     Document Type: Review

References (33)

1. GONZALEZ FJ, SKODA RC, KIMURA S et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature (1988) 331(6155):442-446.
2. EVANS WE, RELLING MV: Pharmacogenomics: Translating functional genomics into rational therapies. Science (1999) 286(5439):487-491. A recent review documenting roles of different CYP polymorphisms.
3. INGELMAN-SUNDBERG M, OSCARSON M, MCLELLAN RA: Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci. (1999) 20(8):342-349. A comprehensive review of the drug metabolism area.
4. HALUSHKA MK, FAN J-B, BENTLEY K et al.: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homcostasis. Nature Genet. (1999) 22(3):239-247. One of the first reports documenting large-scale SNP screening in the hypertension area.
5. CARGILL M, ALTSHULER D, IRELAND J et al.: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature Genet. (1999) 22(3):231-238. One of the first reports evaluating polymorphism frequency in different genomic regions.
6. NICKERSON DA, TAYLOR SL, WEISS KM et al.: DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. Nature Genet.(1998) 19(3):233-240.
7. RIEDER MJ, TAYLOR SL, CLARCK AG et al.: Sequence variation in the human angiotensin converting enzyme. Nature Genet. (1999) 22(1)09-62. SNP screening over an entire gene and in different ethnic groups.
8. PROWS DR, PROWS CA: Optimizing drug therapy based on genetic differences: implications for the clinical setting. AACN Clin. Issues (1998) 9(4):499-512.
9. BURT VL, WHELTON P, ROCCELLA EJ: Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension (1995) 25:305-313.
10. BANEGAS JR, RODRÍGUEZ-ARTALEJO F, DE LA CRUZ TOOCA JJ et al.: Blood pressure in Spain. Distribution, Awareness, Control, and benefits of a reduction in average pressure. Hypertension (1998) 32:998-1002.
11. CHAMONTIN B, POGGI L, LANG T et al.: Prevalence, treatment, and control of hypertension in the French population. Data from a survey on high blood pressure in general practice, 1994. Am. J. Hypertens. (1998) 11:759-762.
12. COLHOUN HM, DONG W, POULTER N: Blood pressure screening, management and control in England: results from the health survey for England 1994. J. Hypertens. (1998) 16:747-752.
13. KOCHAK MS, TROTTIER D, KOTECKI G et al.: Sequential monotherapy of hypertension. J. Clin. Pharmacol. (1994) 34:1173-1176.
14. DICKERSON JEC, HINGORAMI AD, ASHBY MJ et al.: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet (1999) 353:2008-2013. Innovative study documenting individualised variation in patient responses to different antihypertensive drug class treatments.
15. LIGGETT SB: Polymorphisms of the beta2-adrenergic receptor and asthma. Am. J. Respir. Crit. Care Med.(1997) 156(4 Pt 2):S156-162.
16. LIMA JJ, THOMASON DB, MOHAMED MH et al.: Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmaco. Ther. (1999) 65(5):519-525.
17. MARTINEZ FD, GRAVES PE, BALDINI M et al.: Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. (1997) 100(12):3184-3188.
18. DRAZEN JM, YANDAVA CN, DUBE L et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. (1999) 22(2):168-170. An example of the importance of genetic variation and response to asthma treatment.
19. JEUNEMAITRE X, SOUBRIER F, KOTELEVTSEV YV et al.: Molecular basis of human hypertension: role of angiotensinogen. Cell (1992) 71(1):169-180. First report to demonstrate the extent of genetic variation in the RAAS pathway.
20. HINGORANI AD, JIA H, STEVENS PA et al.: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. (1995) 13(12 Pt 2):1602-1609.
21. DUDLEY C, KEAVNEY B, CASADEI B et al.: Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J. Hypertens. (1996) 14:259-262.
22. OHMICHI N, IWAI N, UCHIDA Y et al.: Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens. (1997) 10(8):951-955.
23. VAN DER KLEIJ FG, NAVIS GJ, GANSEVOORT RT et al.: ACE polymorphism does not determine short-term renal response to ACE- inhibition in proteinuric patients. Nephrol. Dial. Transplant. (1997) 12(Suppl. 2):42-46.
24. DE MAAT MP, JUKEMA JW, YE S et al.: Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restcnosis. Am J. Cardiol. (1999) 83(6):852-856.
25. KUIVENHOVEN JA, JUKEMA JW, ZWINDERMAN AH et al.: The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N. Engl. J. Med. (1998) 338(2):86-93.
26. 2A receptor gene and response to clozapine. Mol. Psychiatry(1998) 3(1):61-66. One of the first reports detailing the role of SNPs in schizophrenia treatment.
27. ARRANZ MJ, LI T, MUNRO J et al.: Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics (1998) 8(6):481-484.
28. 4 receptor and response to antipsychotic drugs. Psychopharmacology (1999) 141(1):6-10.
29. SMERALDI E, ZANARDI R, BENEDETTI F et al.: Polymorphism within the promoter of the scrotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry(1998) 3(6):508-511. One of the first reports to document the importance of promoter polymorphisms in depression treatment responses.
30. PENNISI E: A closer look at SNPs suggests difficulties [news]. Science (1998) 281(5384):1787-1789. A meeting review that includes examples of what cannot be achieved by SNP analysis alone.
31. CAMBIEN F, POIRIER O, LECERF L et al.: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature (1992) 359:641-644. A trend-setting study which triggered a number of further genetic association investigations in the cardiovascular therapeutic area.
32. LINDPAINTER K, PFEFFER MA, KREUTZ R et al.: A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N. Engl. J. Med. (1995) 332:706-711. A study which failed to reproduce the results documented in reference [31], and so instigated a long-standing controversy.
33. HOLTZMAN NA: Are genetic tests adequately regulated? Science (1999) 286:409.